TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
09/09/2022 - 07:30 AM
Fireside chat available for on demand download beginning Monday, September 12 2022 at 7:00 AM ET
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate virtually in a fireside chat at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022.
A webcast of the fireside chat will be available for on demand download beginning on Monday, September 12, 2022, at 7:00 AM ET on the conference website. The webcast will also be available on TG’s website at http://ir.tgtherapeutics.com/events .ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com , and follow us on Twitter @TGTherapeutics and Linkedin . CONTACT:
Investor Relations Email: ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6
TGTX Rankings
#924 Ranked by Stock Gains
TGTX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
New York
About TGTX
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".